Provided by Tiger Trade Technology Pte. Ltd.

Skye Bioscience Inc.

0.2800
-0.0004-0.14%
Post-market: 0.2763-0.0037-1.30%19:49 EDT
Volume:974.58K
Turnover:263.16K
Market Cap:9.84M
PE:-0.22
High:0.2840
Open:0.2804
Low:0.2550
Close:0.2804
52wk High:4.99
52wk Low:0.2550
Shares:35.13M
Float Shares:22.95M
Volume Ratio:0.23
T/O Rate:4.25%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.2800
EPS(LYR):-1.4100
ROE:-233.87%
ROA:-96.22%
PB:-19.78
PE(LYR):-0.20

Loading ...

Company Profile

Company Name:
Skye Bioscience Inc.
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
- -
Office Location:
11250 El Camino Real,Suite 100,San Diego,California,United States
Zip Code:
92130
Fax:
- -
Introduction:
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Directors

Name
Position
Paul Grayson
Chairman of the Board
Punit Dhillon
Chief Executive Officer,Director and President
Andrew J. Schwab
Independent Director
Annalisa Jenkins
Independent Director
Deborah Charych
Independent Director
Karen Smith
Independent Director

Shareholders

Name
Position
Punit Dhillon
Chief Executive Officer,Director and President
Tu Diep
Chief Operating Officer
John P. Sharp
Chief Financial Officer
Chris Twitty
Chief Scientific Officer